Powered by

Mundipharma launches Pelmeg®?(pegfilgrastim) biosimilar in Europe

Feb 05, 2019 - Business Wire
Mergers and Acquisitions

The Mundipharma network of independent associated companies today announced the launch of Pelmeg® (pegfilgrastim), a biosimilar of Neulasta® following European Commission (EC) approval in November 2018.2 Pelmeg is the fourth biosimilar medicine to be commercialised by Mundipharma, expanding its portfolio and commercial footprint across Europe. It was developed by Cinfa Biotech which was acquired by Mundipharma and announced in October 2018 .

Now available in Germany, the Netherlands and ...